NASDAQ:AUPH Aurinia Pharmaceuticals Q1 2025 Earnings Report $8.00 -0.11 (-1.36%) As of 05/9/2025 04:00 PM Eastern Earnings HistoryForecast Aurinia Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS $0.09Beat/MissN/AOne Year Ago EPSN/AAurinia Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$61.06 millionBeat/MissN/AYoY Revenue GrowthN/AAurinia Pharmaceuticals Announcement DetailsQuarterQ1 2025Date5/12/2025TimeBefore Market OpensConference Call DateMonday, May 12, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Aurinia Pharmaceuticals Earnings Headlines2AUPH : Uncovering Potential: Aurinia Pharmaceuticals's Earnings PreviewMay 9 at 4:36 PM | benzinga.comAurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025May 5, 2025 | financialpost.comTrump to redistribute trillions of dollars What’s most shocking about this list for me is stock #2. It’s primed to be the biggest beneficiary of the DOGE administration’s efforts to eradicate the filth and corruption plaguing our government. But the thing is… it’s actually not an Elon stock.May 10, 2025 | Porter & Company (Ad)Glass Lewis Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General MeetingMay 1, 2025 | finance.yahoo.comISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General MeetingApril 29, 2025 | uk.finance.yahoo.comAurinia Pharmaceuticals: Shareholder Pressure And Sales GrowthApril 26, 2025 | seekingalpha.comSee More Aurinia Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aurinia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aurinia Pharmaceuticals and other key companies, straight to your email. Email Address About Aurinia PharmaceuticalsAurinia Pharmaceuticals (NASDAQ:AUPH), a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.View Aurinia Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery?Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming?DexCom Stock: Earnings Beat and New Market Access Drive Bull CaseDisney Stock Jumps on Earnings—Is the Magic Sustainable? Upcoming Earnings Petróleo Brasileiro S.A. - Petrobras (5/12/2025)Simon Property Group (5/12/2025)JD.com (5/13/2025)NU (5/13/2025)Sony Group (5/13/2025)SEA (5/13/2025)Cisco Systems (5/14/2025)Toyota Motor (5/14/2025)Copart (5/15/2025)NetEase (5/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
